Abbott Laboratories $ABT Shares Sold by Mesirow Financial Investment Management Inc.

Mesirow Financial Investment Management Inc. lessened its holdings in shares of Abbott Laboratories (NYSE:ABT) by 4.7% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 162,396 shares of the healthcare product maker’s stock after selling 8,028 shares during the quarter. Mesirow Financial Investment Management Inc.’s holdings in Abbott Laboratories were worth $20,346,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Harbor Capital Advisors Inc. acquired a new stake in Abbott Laboratories during the 4th quarter worth approximately $27,000. Cloud Capital Management LLC acquired a new stake in Abbott Laboratories during the 3rd quarter worth approximately $29,000. Guerra Advisors Inc acquired a new stake in Abbott Laboratories during the 3rd quarter worth approximately $31,000. Bridge Generations Wealth Management LLC acquired a new stake in Abbott Laboratories during the 3rd quarter worth approximately $33,000. Finally, Copia Wealth Management acquired a new stake in Abbott Laboratories during the 3rd quarter worth approximately $38,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Analyst Ratings Changes

ABT has been the subject of a number of research analyst reports. Stifel Nicolaus dropped their target price on shares of Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating for the company in a research report on Friday, April 17th. Sanford C. Bernstein lowered their price objective on shares of Abbott Laboratories from $125.00 to $110.00 and set an “outperform” rating for the company in a research report on Friday, April 17th. Royal Bank Of Canada lowered their price objective on shares of Abbott Laboratories from $135.00 to $130.00 and set an “outperform” rating for the company in a research report on Friday, April 17th. Bank of America lowered their price objective on shares of Abbott Laboratories from $150.00 to $120.00 and set a “buy” rating for the company in a research report on Friday, April 17th. Finally, Barclays lowered their price objective on shares of Abbott Laboratories from $144.00 to $143.00 and set an “overweight” rating for the company in a research report on Monday, April 20th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $119.43.

Trending Headlines about Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Recent insider-buying coverage highlighted Abbott alongside other companies with insider purchases, which can be interpreted as a sign of confidence from management or executives. Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell (ABT)
• Positive Sentiment: Wall Street sentiment remains relatively constructive, with articles noting that analysts are still broadly optimistic on Abbott and that the stock’s dividend yield has risen to a decade-high level, which may attract value-oriented investors. Is Abbott (ABT) a Buy as Wall Street Analysts Look Optimistic?
• Neutral Sentiment: Abbott is also being highlighted in broader healthcare and regenerative-medicine market research, reinforcing that it remains a major player in long-term growth markets, though this is not an immediate stock catalyst. Australia Regenerative Medicine Market Research Trends and Forecasts Report 2026-2035 Featuring Prominent Players Such as Abbott Laboratories, Astellas Pharma, and Roche
• Negative Sentiment: Investors remain focused on Abbott’s post-earnings weakness, including concerns about Exact Sciences dilution, legal risks, and soft diagnostics trends, which have weighed on sentiment and helped keep shares depressed. Abbott Stock at 52-Week Low After Q1 Earnings: Book Profits or Hold?
• Negative Sentiment: Older commentary also pointed to Abbott trading at a low valuation after the Exact Sciences deal and legal judgments, suggesting the market is still discounting uncertainty around earnings quality and integration costs. Abbott’s dividend yield near decade peak, signaling rare buying opportunity

Abbott Laboratories Stock Down 0.6%

ABT stock opened at $83.83 on Thursday. Abbott Laboratories has a twelve month low of $81.97 and a twelve month high of $139.06. The company has a current ratio of 1.39, a quick ratio of 1.01 and a debt-to-equity ratio of 0.56. The company has a market capitalization of $146.02 billion, a P/E ratio of 23.48, a PEG ratio of 1.41 and a beta of 0.65. The firm has a 50 day simple moving average of $100.17 and a 200-day simple moving average of $113.85.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, topping analysts’ consensus estimates of $1.14 by $0.01. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The business had revenue of $11.16 billion during the quarter, compared to the consensus estimate of $10.99 billion. During the same quarter last year, the company earned $1.09 earnings per share. The business’s quarterly revenue was up 7.8% compared to the same quarter last year. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. On average, equities research analysts predict that Abbott Laboratories will post 5.48 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 3.0%. The ex-dividend date of this dividend is Wednesday, April 15th. Abbott Laboratories’s payout ratio is currently 70.59%.

Insider Transactions at Abbott Laboratories

In other Abbott Laboratories news, EVP Daniel Gesua Sive Salvadori sold 885 shares of Abbott Laboratories stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $102,288.30. Following the completion of the transaction, the executive vice president owned 146,377 shares of the company’s stock, valued at $16,918,253.66. The trade was a 0.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, SVP Eric Shroff sold 709 shares of Abbott Laboratories stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $81,946.22. Following the completion of the transaction, the senior vice president directly owned 39,164 shares of the company’s stock, valued at approximately $4,526,575.12. This represents a 1.78% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 3,055 shares of company stock valued at $353,097 over the last quarter. Insiders own 0.46% of the company’s stock.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.